1. except when included in schedule 4
2. (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:
   1. cultivated or produced, or in products manufactured, in accordance with the narcotic drugs act 1967; and/or
   2. for use in products manufactured in accordance with the narcotic drugs act 1967; and/or
   3. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
   4. in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
      except when:
      1. it is a product to which item 4, 8, 10, 11 or 12 of schedule 5a to the therapeutic goods regulations 1990 applies; or
      2. separately specified in schedule 4; or
      3. separately specified in the nabiximols entry in this schedule; or
      4. in hemp seed oil for purposes other than internal human therapeutic use containing 50 mg/kg or less of cannabinoids
3. except when included in schedule 2, 3 or 4
4. except when included in schedule 4
5. except when included in schedule 2, 3 or 4
6. except when included in schedule 3 or 4
7. (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use
8. (botanical extract of cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use
9. except the alkaloids noscapine in schedule 2 and papaverine when included in schedule 2 or 4
10. except when included in schedule 4
11. except when included in schedule 2 or 4
12. for human therapeutic use
13. when extracted from cannabis for human therapeutic use, when:
    1. included in products manufactured in accordance with the narcotic drugs act 1967; and/or
    2. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the therapeutic goods act 1989; and/or
    3. in therapeutic goods supplied in accordance with the therapeutic goods act 1989,
       except when:
       1. it is in a product to which item 4, 8, 10, 11 or 12 of schedule 5a to the therapeutic goods regulations 1990 applies; or
       2. in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with either of the following warning statements:
          1. not for internal use; or
          2. not to be taken; or
       3. in products for purposes other than for internal human use containing 50 mg/kg or less of tetrahydrocannabinols or
       4. separately specified in the nabiximols entry in this schedule

For further information contact the Duty Pharmaceutical Officer during office hours on (02) 9391 9944.